Shots:
- Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products
- Graviton to get exclusive development and commercialization rights for TDI01 in all territories (Ex- China)
- TDI01 is a targeted inhibitor of ROCK2 is currently being evaluated in a P-I study in the US for the treatment of IPF. The company expect to develop TDI01 for the treatment of various serious diseases
Click here to read full press release/ article | Ref: PRNewswire | Image: PRNewswire
The post Graviton Signs an Exclusive Worldwide License Agreement with Beijing Tide for TDI01 first appeared on PharmaShots.
